BioDiem secures Japanese patent for BDM-I


By Dylan Bushell-Embling
Friday, 24 May, 2013

BioDiem (ASX:BDM) has expanded its IP protection, securing another Japanese patent for antimicrobial compound BDM-I.

The new patent covers BDM-I as a treatment for malaria and the STD trichomoniasis - both protozoic infections.

BioDiem has already secured similar patents in Europe and the US, and also has patents across all three markets covering BDM-I’s treatment of vulvovaginitis infections caused by thrush, gonorrhoea and chlamydia.

“This latest protozoal patent, coupled with our previous vulvovaginitis patent in key markets, means we now have a comprehensive intellectual property set for the treatment of common female genital health complaints,” BioDiem CEO Julie Phillips said.

BioDiem also has BDM-I patents in Canada, China and Singapore. The company has separately licensed hepatitis B and D vaccine technology from the University of Canberra.

The company is evaluating BDM-I against a range of additional targets, including pneumocystosis, fungal infections and tuberculosis, and the parasitic worms that cause schistosomiasis.

BioDiem shares were trading 11.11% higher at $0.03 as of around 2 pm on Thursday.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd